Personalized treatment of gastric cancer remains a major challenge mainly due to lack of an optimal imaging method for detection of early response to treatment. We evaluated the role of Hyperpolarized [1-13C] Pyruvate Magnetic Resonance Spectroscopic Imaging (HP-13C MRSI) for quantitative measurement of early changes in glycolytic metabolism of gastric cancer models upon initiation of afatinib, a pan-receptor tyrosine kinase inhibitor. We showed that HP-13C MRSI is more sensitive for detection of early metabolic changes in gastric cancer after starting treatment with afatinib compared to 18F-FDG PET/MRI, and therefore can be used for early prediction of response to targeted therapies.
This abstract and the presentation materials are available to members only; a login is required.